サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1401418

卵巣がん診断の世界市場規模調査＆予測：診断タイプ別、がんタイプ別、最終用途別、地域別分析、2023-2030年

Global Ovarian Cancer Diagnostics Market Size study & Forecast, by Diagnosis Type, by Cancer Type, by End Use, and Regional Analysis, 2023-2030

出版日
ページ情報
英文
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
卵巣がん診断の世界市場規模調査＆予測：診断タイプ別、がんタイプ別、最終用途別、地域別分析、2023-2030年
出版日: 2023年11月15日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

卵巣がん診断の世界市場は、2022年に約15億3,000万米ドルと評価され、予測期間2023-2030年には6.2％以上の健全な成長率で成長すると予測されています。

卵巣がんは、卵子の生産を担う女性の臓器である卵巣から発生するがんの一種です。このがんは50～79歳の女性に最も多く、世界の高齢者人口の増加に伴い、その罹患率が高まっています。卵巣がんの管理には早期発見と早期治療が重要であり、政府や組織による取り組みが市場成長の原動力となっています。しかし、熟練した専門家の不足が市場成長の妨げとなっています。

世界中で卵巣がんの症例数が増加していることが市場を牽引しています。米国国立がん研究所の報告によると、卵巣がんの新規発症率は女性10万人当たり年間10.3人で、死亡率は女性10万人当たり年間6.3人です。これは、この病気がいかに致命的であるかを示しています。各国政府や組織は、卵巣がんの診断と治療のための研究開発に投資しており、これが市場の成長を後押ししています。さらに、がん治療のためのヘルスケア支出は増加しており、患者がより早く回復するための高度な診断や治療を受けられるようになっています。市場参入企業も、Inex Innovate社の卵巣がん検出用OvaCis Rapid検査などの革新的な製品を発売しており、市場全体の成長を後押ししています。しかし、より高価ながん治療のため、市場成長への課題となっています。米国国立がん研究所の報告書によると、2018年、がん治療にかかる費用は2,011億9,000万米ドルと推定され、人口増加と高齢化により2020年には2,089億米ドルに増加すると予測されています。これは2030年までの市場成長に影響を与えます。

卵巣がん診断の世界市場調査において考慮した主な地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカなどです。北米は2022年の市場を独占しました。同地域の成長は、政府の積極的な取り組み、ヘルスケア支出の増加、主要メーカーの存在にも起因しています。米国がん協会は、2023年に米国で約19,710人の女性が新たに卵巣がんの診断を受け、約13,270人の女性がこの病気で死亡すると推定しています。アジア太平洋地域は、全体的な経済発展、ヘルスケアインフラの改善、可処分所得の増加、消費者の意識の向上などの要因により、予測期間中に大きく成長すると予想されています。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 卵巣がん診断の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 卵巣がん診断の世界市場力学

  • 卵巣がん診断市場の影響分析（2020-2030年）
    • 市場促進要因
      • 卵巣がんの有病率の上昇
      • 早期診断と早期治療の重視の高まり
      • 各国政府による取り組みの増加
    • 市場の課題
      • 訓練を受けた専門家の不足
      • 診断コストの高さ
    • 市場機会
      • がんの診断と治療のためのヘルスケア支出の増加
      • 市場参入企業による革新的な製品発売

第4章 卵巣がん診断の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 卵巣がん診断の世界市場：診断タイプ別

  • 市場スナップショット
  • 卵巣がん診断の世界市場：診断タイプ別、実績 - ポテンシャル分析
  • 卵巣がん診断の世界市場：診断タイプ別推定・予測、2020-2030年
  • 卵巣がん診断市場、サブセグメント分析
    • イメージング
    • 血液検査
    • 生検
    • その他

第6章 卵巣がん診断の世界市場：がんタイプ別

  • 市場スナップショット
  • 卵巣がん診断の世界市場：がんタイプ別、実績 - ポテンシャル分析
  • 卵巣がん診断の世界市場：がんタイプ別推定・予測、2020-2030年
  • 卵巣がん診断市場、サブセグメント分析
    • 上皮性腫瘍
    • 胚細胞腫瘍
    • 間質細胞腫瘍
    • その他

第7章 卵巣がん診断の世界市場：最終用途別

  • 市場スナップショット
  • 卵巣がん診断の世界市場：最終用途別、実績 - ポテンシャル分析
  • 卵巣がん診断の世界市場：最終用途別推定・予測、2020-2030年
  • 卵巣がん診断市場、サブセグメント分析
    • 病院ラボ
    • がん診断センター
    • 研究機関
    • その他

第8章 卵巣がん診断の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 卵巣がん診断市場、地域別市場スナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Abcam plc.
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson Services, Inc.
    • AstraZeneca plc
    • Siemens Healthcare GmbH
    • Quest Diagnostics Incorporated.
    • Thermo Fisher Scientific Inc.
    • Bio-Rad Laboratories Inc.
    • Abbott. Laboratories Inc.

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Ovarian Cancer Diagnostics Market, report scope
  • TABLE 2. Global Ovarian Cancer Diagnostics Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Ovarian Cancer Diagnostics Market estimates & forecasts by Diagnosis Type 2020-2030 (USD Billion)
  • TABLE 4. Global Ovarian Cancer Diagnostics Market estimates & forecasts by Cancer Type 2020-2030 (USD Billion)
  • TABLE 5. Global Ovarian Cancer Diagnostics Market estimates & forecasts by End Use 2020-2030 (USD Billion)
  • TABLE 6. Global Ovarian Cancer Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Ovarian Cancer Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Ovarian Cancer Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Ovarian Cancer Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Ovarian Cancer Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Ovarian Cancer Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Ovarian Cancer Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Ovarian Cancer Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Ovarian Cancer Diagnostics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Ovarian Cancer Diagnostics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia Ovarian Cancer Diagnostics Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA Ovarian Cancer Diagnostics Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Ovarian Cancer Diagnostics Market
  • TABLE 71. List of primary sources, used in the study of global Ovarian Cancer Diagnostics Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Ovarian Cancer Diagnostics Market, research methodology
  • FIG 2. Global Ovarian Cancer Diagnostics Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Ovarian Cancer Diagnostics Market, key trends 2022
  • FIG 5. Global Ovarian Cancer Diagnostics Market, growth prospects 2023-2030
  • FIG 6. Global Ovarian Cancer Diagnostics Market, porters 5 force model
  • FIG 7. Global Ovarian Cancer Diagnostics Market, pest analysis
  • FIG 8. Global Ovarian Cancer Diagnostics Market, value chain analysis
  • FIG 9. Global Ovarian Cancer Diagnostics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Ovarian Cancer Diagnostics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Ovarian Cancer Diagnostics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Ovarian Cancer Diagnostics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Ovarian Cancer Diagnostics Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Ovarian Cancer Diagnostics Market, regional snapshot 2020 & 2030
  • FIG 15. North America Ovarian Cancer Diagnostics Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Ovarian Cancer Diagnostics Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Ovarian Cancer Diagnostics Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Ovarian Cancer Diagnostics Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Ovarian Cancer Diagnostics Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Ovarian Cancer Diagnostics Market is valued at approximately USD 1.53 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2023-2030. Ovarian cancer is a type of cancer that starts in the ovaries, which are the female organs responsible for producing eggs. This cancer is most commonly found in women aged 50 to 79 and is becoming more prevalent as the world's elderly population grows. Early detection and treatment are key in managing ovarian cancer, and initiatives by governments and organizations are driving market growth. However, a lack of skilled professionals hinder the market growth.

The increasing number of cases of ovarian cancer across the globe is driving the market. According to a report by the National Cancer Institute in the US, the rate of new cases of ovarian cancer is 10.3 per 100,000 women per year, with a death rate of 6.3 per 100,000 women per year. This shows how lethal this disease be. Governments and organizations are investing in research and development for ovarian cancer diagnosis and treatment which is boosting the market growth. such as the Ovarian Cancer Research Alliance (OCRA), a non-profit organization. Additionally, healthcare expenditure for cancer treatment is increasing, allowing patients to access advanced diagnostics and treatment for faster recovery. Market players are also launching innovative products, such as Inex Innovate's OvaCis Rapid test for ovarian cancer detection, which boosts the overall market growth. However, due to costlier cancer treatment it poses challenges to market growth. According to the report of the National Cancer Institute, in 2018, costs for cancer care were estimated at USD 201.19 billion, projected to increase to USD 208.9 billion in 2020 due to population growth and aging. This impact market growth until 2030.

The key regions considered for the Global Ovarian Cancer Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022. The region's growth can also be attributed to favorable government initiatives, increased healthcare expenditure, and the presence of key manufacturers. The American Cancer Society estimates that about 19,710 women in the US would be receiving a new diagnosis of ovarian cancer in 2023, with approximately 13,270 women dying from the disease. Ovarian cancer ranks fifth in cancer deaths among women, in U.S. Asia Pacific is expected to grow significantly over the forecast period, owing to factors such as overall economic development, improved healthcare infrastructure, increased disposable income, and greater consumer awareness.

Major market player included in this report are:

  • Abcam plc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • AstraZeneca plc
  • Siemens Healthcare GmbH
  • Quest Diagnostics Incorporated.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • Abbott. Laboratories Inc.

Recent Developments in the Market:

  • In November 2022, Myriad Genetics Inc. announced, it had acquired Gateway Genomics, LLC to strengthen its portfolio of Women's Health products. This move aims to enhance their Women's Health products portfolio, providing personalized genetic tests that can be accessed during and after a woman's reproductive stage. With SneakPeek, Myriad can now offer genetic insights earlier in pregnancy, providing women with valuable data throughout their lifetime. The company's Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer Test with Risk Scores for all ancestries are expected to increase revenue.
  • In November 2022, Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay became the first IHC-based companion diagnostic to receive FDA approval. It can identify ovarian cancer patients eligible for ELAHERE, providing a new option for treatment.
  • In November 2021, the USFDA approved an imaging drug called Cytalux (pafolcianine) that illuminates ovarian cancer tissue when exposed to fluorescent light, making it easier and more precise for surgeons to remove the cancer.

Global Ovarian Cancer Diagnostics Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Diagnosis Type, Cancer Type, End Use, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Diagnosis Type:

  • Imaging
  • Blood Test
  • Biopsy
  • Others

By Cancer Type:

  • Epithelial Tumor
  • Germ Cell Tumor
  • Stromal Cell Tumor
  • Others

By End Use:

  • Hospital Laboratories
  • Cancer Diagnostic Centers
  • Research Institutes
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Ovarian Cancer Diagnostics Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Ovarian Cancer Diagnostics Market, by Diagnosis Type, 2020-2030 (USD Billion)
    • 1.2.3. Ovarian Cancer Diagnostics Market, by Cancer Type, 2020-2030 (USD Billion)
    • 1.2.4. Ovarian Cancer Diagnostics Market, by End Use, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Ovarian Cancer Diagnostics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Ovarian Cancer Diagnostics Market Dynamics

  • 3.1. Ovarian Cancer Diagnostics Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of ovarian cancer
      • 3.1.1.2. Increasing emphasis on early diagnosis & treatment
      • 3.1.1.3. Increase in the number of initiatives by governments
    • 3.1.2. Market Challenges
      • 3.1.2.1. Lack of trained professionals
      • 3.1.2.2. High Cost of Diagnosis
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing Healthcare Expenditure for Cancer Diagnosis and Treatment
      • 3.1.3.2. Innovative launches by the market players

Chapter 4. Global Ovarian Cancer Diagnostics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Ovarian Cancer Diagnostics Market, by Diagnosis Type

  • 5.1. Market Snapshot
  • 5.2. Global Ovarian Cancer Diagnostics Market by Diagnosis Type, Performance - Potential Analysis
  • 5.3. Global Ovarian Cancer Diagnostics Market Estimates & Forecasts by Diagnosis Type 2020-2030 (USD Billion)
  • 5.4. Ovarian Cancer Diagnostics Market, Sub Segment Analysis
    • 5.4.1. Imaging
    • 5.4.2. Blood Test
    • 5.4.3. Biopsy
    • 5.4.4. Others

Chapter 6. Global Ovarian Cancer Diagnostics Market, by Cancer Type

  • 6.1. Market Snapshot
  • 6.2. Global Ovarian Cancer Diagnostics Market by Cancer Type, Performance - Potential Analysis
  • 6.3. Global Ovarian Cancer Diagnostics Market Estimates & Forecasts by Cancer Type 2020-2030 (USD Billion)
  • 6.4. Ovarian Cancer Diagnostics Market, Sub Segment Analysis
    • 6.4.1. Epithelial Tumor
    • 6.4.2. Germ Cell Tumor
    • 6.4.3. Stromal Cell Tumor
    • 6.4.4. Others

Chapter 7. Global Ovarian Cancer Diagnostics Market, by End Use

  • 7.1. Market Snapshot
  • 7.2. Global Ovarian Cancer Diagnostics Market by End Use, Performance - Potential Analysis
  • 7.3. Global Ovarian Cancer Diagnostics Market Estimates & Forecasts by End Use 2020-2030 (USD Billion)
  • 7.4. Ovarian Cancer Diagnostics Market, Sub Segment Analysis
    • 7.4.1. Hospital Laboratories
    • 7.4.2. Cancer Diagnostic Centers
    • 7.4.3. Research Institutes
    • 7.4.4. Others

Chapter 8. Global Ovarian Cancer Diagnostics Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Ovarian Cancer Diagnostics Market, Regional Market Snapshot
  • 8.4. North America Ovarian Cancer Diagnostics Market
    • 8.4.1. U.S. Ovarian Cancer Diagnostics Market
      • 8.4.1.1. Diagnosis Type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Cancer Type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. End Use breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Ovarian Cancer Diagnostics Market
  • 8.5. Europe Ovarian Cancer Diagnostics Market Snapshot
    • 8.5.1. U.K. Ovarian Cancer Diagnostics Market
    • 8.5.2. Germany Ovarian Cancer Diagnostics Market
    • 8.5.3. France Ovarian Cancer Diagnostics Market
    • 8.5.4. Spain Ovarian Cancer Diagnostics Market
    • 8.5.5. Italy Ovarian Cancer Diagnostics Market
    • 8.5.6. Rest of Europe Ovarian Cancer Diagnostics Market
  • 8.6. Asia-Pacific Ovarian Cancer Diagnostics Market Snapshot
    • 8.6.1. China Ovarian Cancer Diagnostics Market
    • 8.6.2. India Ovarian Cancer Diagnostics Market
    • 8.6.3. Japan Ovarian Cancer Diagnostics Market
    • 8.6.4. Australia Ovarian Cancer Diagnostics Market
    • 8.6.5. South Korea Ovarian Cancer Diagnostics Market
    • 8.6.6. Rest of Asia Pacific Ovarian Cancer Diagnostics Market
  • 8.7. Latin America Ovarian Cancer Diagnostics Market Snapshot
    • 8.7.1. Brazil Ovarian Cancer Diagnostics Market
    • 8.7.2. Mexico Ovarian Cancer Diagnostics Market
  • 8.8. Middle East & Africa Ovarian Cancer Diagnostics Market
    • 8.8.1. Saudi Arabia Ovarian Cancer Diagnostics Market
    • 8.8.2. South Africa Ovarian Cancer Diagnostics Market
    • 8.8.3. Rest of Middle East & Africa Ovarian Cancer Diagnostics Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Abcam plc.
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. F. Hoffmann-La Roche Ltd.
    • 9.3.3. GlaxoSmithKline plc
    • 9.3.4. Johnson & Johnson Services, Inc.
    • 9.3.5. AstraZeneca plc
    • 9.3.6. Siemens Healthcare GmbH
    • 9.3.7. Quest Diagnostics Incorporated.
    • 9.3.8. Thermo Fisher Scientific Inc.
    • 9.3.9. Bio-Rad Laboratories Inc.
    • 9.3.10. Abbott. Laboratories Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption